

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/00	A1	(11) International Publication Number: WO 95/25530 (43) International Publication Date: 28 September 1995 (28.09.95)
(21) International Application Number: PCT/US95/03535 (22) International Filing Date: 21 March 1995 (21.03.95) (30) Priority Data: 08/217,188 24 March 1994 (24.03.94) US (71) Applicants: LUDWIG INSTITUTE FOR CANCER RE- SEARCH [CH/US]; 1345 Avenue of the Americas, New York, NY 10105 (US). UNIVERSITY OF LEIDEN [NL/NL]; Stationsweg 46, NL-2333 AA Leiden (NL). (72) Inventors: MELIEF, Cornelis, J., M.; Building 1, E3-0, Rijnsburgerweg 10, NL-2333 AA Leiden (NL). VISSEREN, M., W.; Building 1, E3-0, Rijnsburgerweg 10, NL-2333 AA Leiden (NL). KAST, W., M.; Building 1, E3-0, Rijnsburgerweg 10, NL-2333 AA Leiden (NL). VAN DER BRUGGEN, Pierre; Avenue Hippocrate 74, UCL 7459, B- 1200 Brussels (BE). BOON-FALLEUR, Thierry; Avenue Hippocrate 74, UCL 7459, B-1200 Brussels (BE). (74) Agent: HANSON, Norman, D.; Felfe & Lynch, 805 Third Avenue, New York, NY 10022 (US).		(81) Designated States: AU, CA, CN, FI, JP, NO, NZ, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: ISOLATED TUMOR REJECTION ANTIGEN PRECURSOR MAGE-2 DERIVED PEPTIDES, AND USES THEREOF (57) Abstract The invention describes peptides derived from tumor rejection antigen precursor MAGE-2. These peptides bind with HLA-A2 molecules, thus presenting complexes which provoke cytolytic T cell production. The resulting "CTLs" are specific for complexes of HLA-A2 and the peptide. The complexes can be used to generate monoclonal antibodies. The cytolytic T cells produced may be used in the context of immunotherapy, such as adoptive transfer.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

ISOLATED TUMOR REJECTION ANTIGEN PRECURSOR
MAGE-2 DERIVED PEPTIDES, AND USES THEREOF

FIELD OF THE INVENTION

5 This invention relates to immunogenetics and to
peptide chemistry. More particularly, it relates to
nonapeptides useful in various ways, including immunogens
and as ligands for the HLA-A2 molecule. More particularly,
it relates to a so-called "tumor rejection antigen",
10 derived from the tumor rejection antigen precursor encoded
by gene MAGE-2, and presented by the MHC-class I molecule
HLA-A2.

BACKGROUND AND PRIOR ART

15 The study of the recognition or lack of recognition of
cancer cells by a host organism has proceeded in many
different directions. Understanding of the field presumes
some understanding of both basic immunology and oncology.

20 Early research on mouse tumors revealed that these
displayed molecules which led to rejection of tumor cells
when transplanted into syngeneic animals. These
molecules are "recognized" by T-cells in the recipient
animal, and provoke a cytolytic T-cell response with lysis
of the transplanted cells. This evidence was first
obtained with tumors induced in vitro by chemical
carcinogens, such as methylcholanthrene. The antigens
25 expressed by the tumors and which elicited the T-cell
response were found to be different for each tumor. See
Prehn, et al., J. Natl. Canc. Inst. 18: 769-778 (1957);
Klein et al., Cancer Res. 20: 1561-1572 (1960); Gross,
Cancer Res. 3: 326-333 (1943), Basombrio, Cancer Res. 30:
30 2458-2462 (1970) for general teachings on inducing tumors
with chemical carcinogens and differences in cell surface
antigens. This class of antigens has come to be known as
"tumor specific transplantation antigens" or "TSTAs".
Following the observation of the presentation of such
35 antigens when induced by chemical carcinogens, similar

results were obtained when tumors were induced in vitro via ultraviolet radiation. See Kripke, J. Natl. Canc. Inst. 53: 333-1336 (1974).

While T-cell mediated immune responses were observed for the types of tumor described supra, spontaneous tumors were thought to be generally non-immunogenic. These were therefore believed not to present antigens which provoked a response to the tumor in the tumor carrying subject. See Hewitt, et al., Brit. J. Cancer 33: 241-259 (1976).

The family of tum antigen presenting cell lines are immunogenic variants obtained by mutagenesis of mouse tumor cells or cell lines, as described by Boon et al., J. Exp. Med. 152: 1184-1193 (1980), the disclosure of which is incorporated by reference. To elaborate, tum antigens are obtained by mutating tumor cells which do not generate an immune response in syngeneic mice and will form tumors (i.e., "tum⁺" cells). When these tum⁺ cells are mutagenized, they are rejected by syngeneic mice, and fail to form tumors (thus "tum"). See Boon et al., Proc. Natl. Acad. Sci. USA 74: 272 (1977), the disclosure of which is incorporated by reference. Many tumor types have been shown to exhibit this phenomenon. See, e.g., Frost et al., Cancer Res. 43: 125 (1983).

It appears that tum variants fail to form progressive tumors because they initiate an immune rejection process. The evidence in favor of this hypothesis includes the ability of "tum" variants of tumors, i.e., those which do not normally form tumors, to do so in mice with immune systems suppressed by sublethal irradiation, Van Pel et al., Proc. Natl. Acad. Sci. USA 76: 5282-5285 (1979); and the observation that intraperitoneally injected tum cells of mastocytoma P815 multiply exponentially for 12-15 days, and then are eliminated in only a few days in the midst of an influx of lymphocytes and macrophages (Uyttenhove et al., J. Exp. Med. 152: 1175-1183 (1980)). Further evidence includes the observation that mice acquire an immune memory

which permits them to resist subsequent challenge to the same tum variant, even when immunosuppressive amounts of radiation are administered with the following challenge of cells (Boon et al., Proc. Natl, Acad. Sci. USA 74: 272-275 (1977); Van Pel et al., supra; Uyttenhove et al., supra).

Later research found that when spontaneous tumors were subjected to mutagenesis, immunogenic variants were produced which did generate a response. Indeed, these variants were able to elicit an immune protective response against the original tumor. See Van Pel et al., J. Exp. Med. 157: 1992-2001 (1983). Thus, it has been shown that it is possible to elicit presentation of a so-called "tumor rejection antigen" in a tumor which is a target for a syngeneic rejection response. Similar results have been obtained when foreign genes have been transfected into spontaneous tumors. See Fearson et al., Cancer Res. 48: 2975-1980 (1988) in this regard.

A class of antigens has been recognized which are presented on the surface of tumor cells and are recognized by cytolytic T cells, leading to lysis. This class of antigens will be referred to as "tumor rejection antigens" or "TRAs" hereafter. TRAs may or may not elicit antibody responses. The extent to which these antigens have been studied, has been via cytolytic T cell characterization studies, in vitro i.e., the study of the identification of the antigen by a particular cytolytic T cell ("CTL" hereafter) subset. The subset proliferates upon recognition of the presented tumor rejection antigen, and the cells presenting the antigen are lysed. Characterization studies have identified CTL clones which specifically lyse cells expressing the antigens. Examples of this work may be found in Levy et al., Adv. Cancer Res. 24: 1-59 (1977); Boon et al., J. Exp. Med. 152: 1184-1193 (1980); Brunner et al., J. Immunol. 124: 1627-1634 (1980); Maryanski et al., Eur. J. Immunol. 124: 1627-1634 (1980); Maryanski et al., Eur. J. Immunol. 12: 406-412 (1982); Palladino et al., Canc. Res. 47: 5074-5079 (1987). This

type of analysis is required for other types of antigens recognized by CTLs, including minor histocompatibility antigens, the male specific H-Y antigens, and the class of antigens referred to as "tum-" antigens, and discussed herein.

A tumor exemplary of the subject matter described supra is known as P815. See DePlaen et al., Proc. Natl. Acad. Sci. USA 85: 2274-2278 (1988); Szikora et al., EMBO J 9: 1041-1050 (1990), and Sibille et al., J. Exp. Med. 172: 35-45 (1990), the disclosures of which are incorporated by reference. The P815 tumor is a mastocytoma, induced in a DBA/2 mouse with methylcholanthrene and cultured as both an in vitro tumor and a cell line. The P815 line has generated many tumor variants following mutagenesis, including variants referred to as P91A (DePlaen, supra), 35B (Szikora, supra), and P198 (Sibille, supra). In contrast to tumor rejection antigens - and this is a key distinction - the tumor antigens are only present after the tumor cells are mutagenized. Tumor rejection antigens are present on cells of a given tumor without mutagenesis. Hence, with reference to the literature, a cell line can be tumor⁺, such as the line referred to as "P1", and can be provoked to produce tumor variants. Since the tumor phenotype differs from that of the parent cell line, one expects a difference in the DNA of tumor cell lines as compared to their tumor⁺ parental lines, and this difference can be exploited to locate the gene of interest in tumor cells. As a result, it was found that genes of tumor variants such as P91A, 35B and P198 differ from their normal alleles by point mutations in the coding regions of the gene. See Szikora and Sibille, supra, and Lurquin et al., Cell 58: 293-303 (1989). This has proved not to be the case with the TRAs of this invention. These papers also demonstrated that peptides derived from the tumor antigen are presented by the L^d molecule for recognition by CTLs. P91A is presented by L^d, P35 by D^d and P198 by K^d.

PCT application PCT/US92/04354, filed on May 22, 1992 assigned to the same assignee as the subject application, teaches a family of human tumor rejection antigen precursor coding genes, referred to as the MAGE family. Several of these genes are also discussed in van der Bruggen et al., Science 254: 1643 (1991). It is now clear that the various genes of the MAGE family are expressed in tumor cells, and can serve as markers for the diagnosis of such tumors, as well as for other purposes discussed therein. See also Traversari et al., Immunogenetics 35: 145 (1992); van der Bruggen et al., Science 254: 1643 (1991). The mechanism by which a protein is processed and presented on a cell surface has now been fairly well documented. A cursory review of the development of the field may be found in Barinaga, "Getting Some 'Backbone': How MHC Binds Peptides", Science 257: 880 (1992); also, see Fremont et al., Science 257: 919 (1992); Matsumura et al., Science 257: 927 (1992); Latron et al., Science 257: 964 (1992). These papers generally point to a requirement that the peptide which binds to an MHC/HLA molecule be nine amino acids long (a "nonapeptide"), and to the importance of the first and ninth residues of the nonapeptide.

Studies on the MAGE family of genes have now revealed that a particular nonapeptide is in fact presented on the surface of some tumor cells, and that the presentation of the nonapeptide requires that the presenting molecule be HLA-A1. Complexes of the MAGE-1 tumor rejection antigen (the "TRA" or nonapeptide) leads to lysis of the cell presenting it by cytolytic T cells ("CTLs").

Attention is drawn, e.g., to concurrently filed application Serial No. _____ to Traversari et al., and Serial No. _____ to Townsend et al., both of which present work on other, MAGE-derived peptides.

Research presented in, e.g., U.S. patent application Serial No. 07/938,334 filed August 31, 1992, and in U.S. patent application Serial No. 073,103, filed June 7, 1993, when comparing homologous regions of various MAGE genes to

the region of the MAGE-1 gene coding for the relevant nonapeptide, there is a great deal of homology. Indeed, these observations lead to one of the aspects of the invention disclosed and claimed therein, which is a family of nonapeptides all of which have the same N-terminal and C-terminal amino acids. These nonapeptides were described as being useful for various purposes which includes their use as immunogens, either alone or coupled to carrier peptides. Nonapeptides are of sufficient size to constitute an antigenic epitope, and the antibodies generated thereto were described as being useful for identifying the nonapeptide, either as it exists alone, or as part of a larger polypeptide.

These references, especially Serial No. 073,103, showed a connection between HLA-A1 and MAGE-3; however, only about 26% of the caucasian population and 17 % of the negroid population presents HLA-A1 molecules on cell surfaces. Thus, it would be useful to have additional information on peptides presented by other types of MHC molecules, so that appropriate portions of the population may benefit from the research discussed supra.

It has now been found that antigen presentation of MAGE-2 derived peptides set forth, in the disclosure which follows, identifies peptides which complex with MHC class I molecule HLA-A2. The ramifications of this discovery, which include therapeutic and diagnostic uses, are among the subjects of the invention, set forth in the disclosure which follows.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

EXAMPLE 1

Experimental conditions:

All experiments were performed at room temperature unless stated otherwise. All Fmoc protected amino acids, synthesis polymers, peptides and TFA were stored at -20°C.

Peptide synthesis

Peptides were synthesized by solid phase strategies on an automated multiple peptide synthesizer (Abimed AMS 422) (see Gausepohl and Frank, 1990; Gausepohl et al., (1990).

5 The peptides were made in various runs, in each of which 48 different peptides were synthesized simultaneously.

10 Tentagel S AC (Rapp et al., 1990; Sheppard and Williams, 1982), a graft polymer of polyethyleneglycol spacer arms on a polystyrene matrix, was used as a resin (40-60 mg per peptide, 10 μ mol Fmoc amino acid loading).

15 Repetitive couplings were performed by adding a mixture of 90 μ l 0.67 M BOP (Gausepohl et al., 1988; Castro et al., 1975) in NMP, 20 μ l NMM in NMP 2/1 (v/v) and 100 μ l of an 0.60 M solution of the appropriate Fmoc amino acid (Fields and Noble, 1990) in NMP (6-fold excess) to each reaction vessel. At 70% of the reaction time approximately 50 μ l dichloromethane was added to each reaction vessel.

20 Fmoc-deprotection was performed by adding 3 times 0.8 ml of piperidine/DMA 1/4 (v/v) to each reaction vessel.

Coupling- and deprotection times were increased as the synthesis proceeded, starting with 30 min and 3 times 3 min respectively.

25 Washings after couplings and Fmoc-deprotections were done with 6 times 1.2 ml DMA. After the required sequence had been reached and the last Fmoc-protection was removed the peptidylresin was washed extensively with DMA, dichloromethane, dichloromethane/ether 1/1 (v/v) and ether respectively, and dried.

30 Peptide cleavage and isolation

35 Cleavage of the peptides from the resin and removal of the side chain protecting groups was performed by adding 6 times 200 μ l TFA/water 19/1 (v/v) at 5 min intervals to each reaction vessel, thus yielding free carboxylic peptides. For Trp-containing peptides TFA/water/ethanethiol 18/1/1/ (v/v/v) was used.

Two hours after the first TFA addition to the peptides were precipitated from the combined filtrates by addition of 10 ml ether/pentane 1/1 (v/v) and cooling to -20°C. The peptides were isolated by centrifugation (-20°C, 2500g, 10 min).

After treatment of the pellet with ether/pentane 1/1 (v/v) and isolation by the same centrifugation procedure, the peptides were dried at 45°C for 15 min.

Each of the peptides was dissolved in 2 ml water (or 2 ml 10 vol.% acetic acid), the solution frozen in liquid nitrogen for 3 min, and lyophilized while being centrifuged (1300 rpm, 8-16 h).

Analysis and purification

The purity of the peptides was determined by reversed phase HPLC; an aliquot of about 50 nmol was dissolved in 100 µl 30 vol.% acetic acid. Of this solution 30 µl was applied to an RP-HPLC system equipped with a ternary solvent system; A: water, B: acetonitrile, C: 2 vol.% TFA in water.

Gradient elution (1.0 ml/min) was performed from 90% A, 5% B, 5% C to 20% A, 75% B, 5% C in 30 min. Detection was at 214 nm.

Samples taken at random were analyzed by mass spectrometry on a PDMS. The 31 binding peptides were all analyzed by mass spectrometry on a PDMS and by quantitative amino acid analysis after hydrolysis on a HP Aminoquant. Of all analyzed samples the difference between calculated and measured masses was within the experimental error (0.1%) as specified by the producer of the equipment used. All amino acid compositions were as expected.

EXAMPLE 2

Peptides

Of all 71 MAGE-2 peptides that had been freeze dried, 1 mg was weighed and dissolved in 10 µl of DMSO. Of all

dissolved peptides a dilution of 0.5 mg/ml in 0.9% NaCl was made and the pH was neutralized to pH 7 with 5% acetic acid diluted in distilled water (CH₃COOH, Merck Darmstadt, Germany: 56-1000) or 1N NaOH diluted in distilled water (Merck Darmstadt, Germany: 6498).

Cells

174CEM.T2 cells were cultured in Iscove's modified Dulbecco's medium (Biochrom KG Seromed Berlin, Germany: F0465) supplemented with 100IU/ml penicillin (Biocades Pharma, Leiderdorp, The Netherlands), 100 µg/ml kanamycin (Sigma St. Louis, USA: K-0254), 2mM glutamine (ICN Biomedicals Inc. Costa Mesa, CA, USA: 15-801-55) and 10% fetal calf serum (FCS, Hyclone Laboratories Inc. Logan, Utah, USA: A-1115-L). Cells were cultured at a density of 2.5 x 10⁵/ml during 3 days at 37°C, 5% CO₂ in humidified air.

Peptide binding

174CEM.T2 cells were washed twice in culture medium without FCS and put in serum-free culture medium to a density of 2 x 10⁶ cells/ml. Of this suspension 40 µl was put into a V bottomed 96 well plate (Greiner GmbH, Frickenhausen, Germany: 651101) together with 10 µl of two fold serial dilutions in 0.9% NaCl of the individual peptide dilutions (ranging from 500 ug/ml to 15.6 µg/ml). The end concentrations range from 200 µg/ml to 3.1 µg/ml peptide with 8x10⁴ 174CEM.T2 cells. This solution was gently agitated for 3 minutes after which an incubation time of 16 hours at 37°C, 5% CO₂ in humified air took place. Then cells were washed once with 100 µl 0.9% NaCl, 0.5% bovine serum albumin (Sigma St. Louis, USA: A-7409), 0.02% NaN₃ (Merck Darmstadt, Germany: 822335). After a centrifuge round of 1200 rpm the pellet was resuspended in 50 µl of saturating amounts of HLA-A2.1 specific mouse monoclonal antibody BB7.2 for 30 minutes at 4°C. Then cells were

10

washed twice and incubated for 30 minutes with F(ab)₂ fragments of goat anti-mouse IgG that had been conjugated with fluorescein isothiocyanate (Tago Inc. Burlingame, CA, USA: 4350) in a dilution of 1:40 and a total volume of 25 μ l.

After the last incubation, cells were washed twice and fluorescence was measured at 488 nanometer on a FACScan flowcytometer (Becton Dickinson, Franklin Lakes, NJ, USA). The concentration at which the 0.5 maximum upregulation of HLA-A2.1 on 174CEM.T2 cells was achieved was determined using graphs in which the fluorescence index was plotted against the peptide concentration. The results are shown in Table I.

TABLE I
Binding affinities of peptides derived from human melanoma associated protein MAGE-2 that fit the HLA-A2.1 motif (compilation of Falk et al., 1991, Hunt et al., 1992 and Nijman et al., 1993).

Peptide No.	sequence	residues	peptide concentration that induces 0.5 maximum FI

	GLEARGEALGL	15- 25	>100 µg/ml
	GLEARGEAL	15- 23	60 µg/ml
	ALGLVGQAQA	22- 30	>100 µg/ml
	GLVGQAQAPA	24- 32	65 µg/ml
2	DLESEFQAA	100-108	>100 µg/ml
	DLESEFQAAI	100-109	>100 µg/ml
	AISRKMVELV	108-117	>100 µg/ml
	AISRKMVEL	108-116	>100 µg/ml
	KMVELVHFL	112-120	40 µg/ml
	KMVELVEFLL	112-121	>100 µg/ml
	KMVELVEFLLL	112-122	>100 µg/ml
	LLKYRAREPV	120-130	>100 µg/ml
	LLKYRAREPV	121-130	>100 µg/ml
	VLRNCODFFPV	139-149	>100 µg/ml
3	VIFSKASEYL	149-158	35 µg/ml
4	YLQLVFGIEV	157-166	35 µg/ml
	YLQLVFGIEVV	157-167	>100 µg/ml
5	OLVFGIEVV	159-167	25 µg/ml
6	OLVFGIEVVVEV	159-169	30 µg/ml
	GIEVVVEVVI	163-172	>100 µg/ml
	PISHLYILV	171-179	55 µg/ml
	ELYILVTCL	174-182	>100 µg/ml
	ELYILVTCLGL	174-184	>100 µg/ml
	YILVTCLGL	176-184	>100 µg/ml
	CLGLSYDGL	181-189	65 µg/ml
	CLGLSYDGLL	181-190	>100 µg/ml
	VMPKTGLLI	195-203	>100 µg/ml
	VMPKTGLLII	195-204	>100 µg/ml
	VMPKTGLLIIV	195-205	>100 µg/ml
	GLLIIVLAI	200-208	>100 µg/ml
	GLLIIVLAI I	200-209	>100 µg/ml
	GLLIIVLAI IA	200-210	>100 µg/ml
	LLIIVLAI I	201-209	>100 µg/ml
	LLIIVLAI IA	201-210	>100 µg/ml
	LLIIVLAI IAI	201-211	>100 µg/ml
	LIIVLAI IA	202-210	>100 µg/ml
	LIIVLAI IAI	202-211	>100 µg/ml
7	IIVLAI IAI	203-211	20 µg/ml
	IIAIEGDCA	208-216	>100 µg/ml
	KIWEELSM	220-228	>100 µg/ml
8	KIWEELSMLEV	220-230	25 µg/ml
	LMQDLVQENYL	246-256	>100 µg/ml
	FLWGPRALI	271-279	65 µg/ml
9	ALIETSYVKV	277-286	20 µg/ml
	ALIETSYVKVL	277-287	>100 µg/ml
10	LIETSYVKV	278-286	30 µg/ml
	LIETSYVKVL	278-287	55 µg/ml
	TLKIGGEPHI	290-299	>100 µg/ml
	HISYPPLERA	298-308	>100 µg/ml

SUBSTITUTE SHEET (RULE 26)

The 174CEM.T2 cell line expresses "empty" and unstable HLA-A2.1 molecule that can be stabilized when a peptide is binding to the peptide presenting groove of these molecules. A stabilized HLA-A2.1 molecule that will not easily degrade is the result of binding of an analyzed peptide. This leads to an increase in cell surface expression of the HLA-A2.1 molecule. The fluorescence index is a measure for the amount of upregulation of HLA-A2.1 molecules. This fluorescence index is calculated according to the following formula:

MF = Mean Fluorescence

$$FI = \text{Fluorescence Index} = \frac{(MF)_{\text{experiment}} - (MF)_{\text{blank}}}{(MF)_{\text{blank}}}$$

Fluorescence Index of the background fluorescence is 0.

Results

In order to identify MAGE-2 peptides that could bind to HLA-A2.1 molecules expressed by 174CEM.T2 cells, the amino acid sequence of MAGE-2 was examined (4). All nine, ten or eleven amino acid long peptides that fitted the published HLA-A2.1 binding motif were examined (Table I).

Only the peptides Nos. 1-11 of Table II were able to upregulates the expression of HLA-A2.1 molecules at a low peptide concentration, indicating their binding to the HLA-A2.1 molecule as described in Example 2. None of the 60 other peptides were able to do this. The results of the fluorescence measurement are given in Table I. The 0.5 maximum upregulation of HLA-A2.1 molecules on 174CEM.T2 cells was determined using graphs in which the FI was plotted against the peptide concentration for each individual peptide.

These experiments indicate that only a limited proportion of peptides that fit the HLA-A2.1 motif have the ability to bind to this HLA molecule with high affinity and are therefore the only candidates of the MAGE-2 protein to

be recognized by human CTL, because CTL recognize peptides only when bound to HLA molecules.

TABLE II

5 Binding affinities of additional peptides derived from human melanoma associated protein MAGE-2 that fit the extended HLA-A2.1 motif (Ruppert et al).

Peptide No.	Sequence	residues	peptide concentration that induces 0.5 maximum FI

10	QTASSSSTL	37-45	>100 µg/ml
	QTASSSSTLV	37-46	>100 µg/ml
1	STLVEVTLGEV	43-53	45 µg/ml
	VTLGEVPAA	48-56	>100 µg/ml
	VTKAEMLESV	130-139	70 µg/ml
15	VTKAEMLESVL	130-140	>100 µg/ml
	VTCLGLSYDGL	179-189	>100 µg/ml
	KTGLLLIIVL	198-206	65 µg/ml
	KTGLLLIIVLA	198-207	80 µg/ml
	KTGLLLIIVLAI	198-208	>100 µg/ml
20	HTLKIGGEPHI	289-299	100 µg/ml

TABLE III

Peptides derived from melanoma protein MAGE-2 binding to HLA-A2.1

5	peptide	Amino acid	region	SEQ
	No.	sequence		ID NO

	1	STLVEVTLGEV	residues 43-53	1
	-	LVEVTLGEV	residues 45-53	2
	2	KMVELVHFL	residues 112-120	3
10	3	VIFSKASEYL	residues 149-158	4
	4	YLQLVFGIEV	residues 157-166	5
	5	QLVFGIEVV	residues 159-167	6
	6	QLVFGIEVVEV	residues 159-169	7
	7	IIVLAIIAI	residues 203-211	8
15	8	KIWEELSMLEV	residues 220-230	9
	9	ALIETSYVKV	residues 277-286	10
	10	LIETSYVKV	residues 278-286	11

EXAMPLE 3

20 This example shows in vitro induction of primary immune response. As an illustration for the possibility to induce primary responses in general, including MAGE-2 peptides, such responses against HPV peptides using the processing defective cell line 174CEM.T2 are shown.

25 The expression of HLA-A2.1 cells (T2) is increased by incubating T2 cells in medium containing relevant peptide. T2 cells will present the relevant peptide bound to HLA-A2.1 in high amount and therefore are good antigen presenting cells (APC). In the response inducing method described recently (Kast et al., 1993) the T2 cell line is
30 used as APC and post-Ficoll mononuclear cells are used as responder cells.

Method

1) Peptide loading of HLA-A2.1 on T2

5 T2 cells in a concentration of 2×10^6 cells per ml were incubated for 13 hours at 37°C in a T 25 flask (Becton Dickinson, Falcon, Plymouth Engeland cat.nr. 3013) in serum-free IMDM (= Iscoves Modified Dulbecco's Medium: Biochrom KG, Seromed Berlin, Germany, cat.nr. F0465) with glutamine (2mM, ICN Biochemicals Inc., Costa Meisa, USA, cat.nr. 15-801-55), antibiotics (100 IU/ml penicillin 10 Brocades Pharma, Leiderdorp, The Netherlands, 100 µg/ml kanamycin (Sigma, St. Louis, USA, K-0245)) and the selected peptide MLDLQPETT in a concentration of 80 µg/ml.

2) Mitomycin C treatment of T2 (APC)

15 These incubated T2 cells were spun down and subsequently treated in a density of 20×10^6 cells/ml with Mitomycin C (50 µg/ml) in serum-free RPMI (Gibco Paislan Scotland, cat.nr 041-02409) medium for one hour at 37°C. Hereafter the T2 cells were washed three times in RPMI.

3) Preparing for primary immune response induction

20 All wells of a 96-well-U-bottom plate (Costar, Cambridge, USA, cat.nr. 3799) were filled with 100,000 Mitomycin C-treated T2 cells in 50 µl serum-free, complete RPMI medium (glutamine (2 mM, ICN Biochemicals Inc., costa Meisa, USA, cat.nr. 15-801-55), penicillin (100 IU/ml, Brocades Pharma, Leiderdorp, The Netherlands), kanamycin 25 (100 µg/ml, Sigma, St. Louis, USA, K-0245)) and the peptide MLDLQPETT in a concentration of 80 µg/ml.

4) Responder cells

30 Responder cells are mononuclear peripheral blood lymphocytes (PBL) of a HLA-A2.1 subtyped donor (= C.B). The PBL were separated from a buffy coat by Ficoll-procedure (Ficoll preparation: Lymphoprep of Nycomedpharma, Oslo, Norway, cat.nr. 105033) and washed two times in RPMI. After separation and washing, the PBL were resuspended in

complete RPMI medium with 30% human pooled serum (HPS) (HPS is tested for a suppression activity in Mixed Lymphocyte Cultures).

5) Incubation of primary immune response

5 400,000 FBL-C.B. in 50 μ l of medium (the medium described in header 4) were added to each well of the 96-well-U-bottom plate already filled with T2 cells and cultured for 7 days at 37°C in an incubator with 5% CO₂ and 90% humidity.

10 6) Restimulation (day 7)

On day 7 after incubation of PBL, peptide MLDLQPETT and T2 cells (headers 1-5), the PBL-C.B. were restimulated with peptide MLDLQPETT. For this purpose all cells and medium out of the 96 wells were harvested. Viable cells
15 were isolated by ficoll-procedure and washed in RPMI. In a new 96-well-U-bottom plate 50,000 of these viable cells were seeded to each well together with 50 μ l complete RPMI medium with 15% HPS. Per well 20,000 autologous, irradiated (3000 rad) PBL and 50,000 autologous, irradiated
20 (10000 rad) EBV-transformed B-lymphocytes (= EBV-C.B.) were added together with 50 μ l of complete RPMI medium with 15% HPS and peptide MLDLQPETT in a concentration of 80 μ g/ml. The cells were cultured for 7 days at 37°C in an incubator with 5% CO₂ and 90% humidity.

25 7) Restimulation (day 14)

On day 14 after incubation of PBL, peptide MLDLQPETT and T2 cells (headers 1-5), the PBL-c.B. were restimulated with peptide MLDLQPETT. To do so the procedure under header 6 is repeated.

30 8) Cloning by Limiting Dilution

On day 21 after incubation of PBL, peptide MLDLQPETT and T2 cells, cells and medium out of the 96 wells were harvested. Viable cells were isolated by Ficoll-procedure

and washed in complete RPMI with 15% HPS. This bulk of viable cells was cloned by Limiting Dilution. Into each well of a new 96-well-U-bottom plate (Costar, Cambridge, USA, cat. nr. 3799) 50 μ l complete RPMI medium with 15% HPS was added together with 100 viable cells (= HPV16 bulk anti MLDLQPETT). For other new 96-well-U-bottom plates this was exactly repeated except for the number of cells for wells: subsequent plates contained 10, 1, or 0.3 cells per well. To all wells 20,000 pooled and irradiated (3000 rad) PBL of four different donors and 10,000 pooled and irradiated (10,000 rad) EBV-transformed B-cells of three different HLA-A2.1 donors (VU-4/518/JY) were added together with 50 μ l of complete RPMI medium with 15% HPS and peptide MLDLQPETT in a concentration of 40 μ g/ml, Leucoagglutinin in a concentration of 2% (Pharmacia, Uppsala, Sweden, cat.nr. 17-063-01), human recombinant IL-2 in a concentration of 120 IU/ml (Eurocetus, Amsterdam, The Netherlands).

9) Expand clones

- 20 Add per well, in a final volume of 100 μ l =>
- 25,000 viable cells
 - 20,000 irradiated PBL-pool (as in header 8)
 - 10,000 irradiated EBV-pool (as in header 8)
 - 2 μ g peptide MLDLQPETT
 - 25 - 6 IU recombinant IL-2.

On day 49 a cytotoxicity assay was performed with 65 clones and one bulk as effector cells and T2 (with or without the relevant peptide MLDLQPETT) as target cells. Background killing is defined as killing of T2 cells incubated with an irrelevant (but HLA-A2.1 binding) peptide: GILGFVFTL. This influenza matrix protein-derived peptide is the epitope for HLA-A2.1 restricted influenza specific CTL.

Most HLA-A2.1 binding peptides were found using the HLA-A2.1 motif (compilation of Rammensee et al., 1991, Hunt

et al., 1992 and Nijman et al., 1993). Only 1 additional HLA-A2.1 binding peptide was found using the extended HLA-A2.1 motif (Ruppert et al., 1993).

The data suggest that the peptides mentioned above are single polypeptides of identified sequences. However, homologs, isoforms or genetic variants of these peptides may exist within or outside the cellular environment. This invention encompasses all such homologs, isoforms or genetic variants of the above peptides provided that they bind to the HLA-A2.1 molecule.

Polypeptides that are homologs of the peptides specifically include those having amino acid sequences which are at least about 40% conserved in relation to the amino acid sequence set forth in Table II, preferentially at least about 60% conserved, and more preferentially at least about 75% conserved.

It will be understood by one of ordinary skill in the art that other variants of the peptides shown above are included with the scope of the present invention. This particularly includes any variants that differ from the above mentioned and synthesized peptides only by conservative amino acid substitution. In particular, replacements of C (cysteine) by A (alanine), S (serine), α -aminobutyric acid and others are included as it is known that cysteine-containing peptides are susceptible to (air) oxidation during synthesis and handling. Many such conservative amino acid substitutions are set forth as sets by Taylor (1986).

Herein the peptides shown above or fragments thereof include any variation in the amino acid sequence, whether by conservative amino acid substitution, deletion, or other processes, provided that the polypeptides bind to the HLA-A2.1 molecule. The fragments of the peptides may be small peptides with sequences of as little as five or more amino acids, said sequence being those disclosed in Table II when said polypeptides bind to the HLA-A2.1 molecule.

Polypeptides larger than the peptides shown are especially included within the scope of the present invention when said polypeptides induce a MAGE-2 specific CTL response in HLA-A2.1 positive individuals and include
5 a (partial) amino acid sequence as set forth in Table II, or conservative substitutions thereof. Such polypeptides may have a length of from 9 to 12, more preferably 9 to 11 or even 9 to 10 amino acids.

This invention includes the use of polypeptides
10 generated by every means, whether genetic engineering, peptide synthesis with solid phase techniques or others. The foregoing peptides may have various chemical modifications made at the terminal ends and still be within the scope of the present invention. Also other chemical
15 modifications are possible, particularly cyclic and dimeric configurations. The term "derivatives" intends to cover all such modified peptides.

The polypeptides of the present invention find utility for the treatment or prevention of diseases involving MAGE-
20 2 expressing cells including melanomas cells and other cancer cells.

For all applications the peptides are administered in an immunogenic form. Since the peptides are relatively short, this may necessitate conjugation with an
25 immunogenicity conferring carrier material such as lipids or others or the use of adjuvants.

The magnitude of a prophylactic or a therapeutic dose of polypeptides of this invention will, of course, vary with the group of patients (age, sex, weight, etcetera),
30 the nature of the severity of the condition to be treated, the particular polypeptide of this invention and its route of administration. Any suitable route of administration may be employed to achieve an effective dosage of a polypeptide identified by this invention, as well as any
35 dosage form well known in the art of pharmacy. In addition the polypeptides may also be administered by controlled release means and/or delivery devices. They may also be

administered in combination with other active substances, such as, in particular, T-cell activating agents like interleukin-2 etc.

5 The peptides of this invention may also be useful for other purposes, such as diagnostic use. For example, they may be used to check whether a vaccination with a peptide according to the invention has been successful. This may be done in vitro by testing whether said peptide is able to activate T cells of the vaccinated person.

10 Other aspects of the invention will be clear to the skilled artisan, and need not be repeated here.

15 The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, it being recognized that various modifications are possible within the scope of the invention.

21

(1) GENERAL INFORMATION:

(i) APPLICANTS: Melief, Cornelis J. M.
Visseren, M. J. W.
Kast; W. M.
van der Bruggen, Pierre
Boon-Falleur, Thierry

(ii) TITLE OF INVENTION: Isolated Tumor Rejection
Antigen Precursor Mage-2 Derived Peptides, and Uses Thereof

(iii) NUMBER OF SEQUENCES: 62

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Felte & Lynch
(B) STREET: 805 Third Avenue
(C) CITY: New York City
(D) STATE: New York
(E) COUNTRY: USA
(F) ZIP: 10022

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Diskette, 5.25 inch, 360 kb
storage
(B) COMPUTER: IBM PS/2
(C) OPERATING SYSTEM: PC-DOS
(D) SOFTWARE: Wordperfect

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: 08/217,188
(B) FILING DATE: 24-MARCH-1994

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Hanson, Norman D.
(B) REGISTRATION NUMBER: 30,946
(C) REFERENCE/DOCKET NUMBER: LUD 5340-PCT

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (212) 688-9200
(B) TELEFAX: (212) 838-3884

22

(2) INFORMATION FOR SEQUENCE ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 11 amino acid residues

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

Ser Thr Leu Val Glu Val Thr Leu Gly Glu Val
1 5 10

(2) INFORMATION FOR SEQUENCE ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 9 amino acid residues

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Leu Val Glu Val Thr Leu Gly Glu Val
1 5

(2) INFORMATION FOR SEQUENCE ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 9 amino acid residues

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

Lys Met Val Glu Leu Val His Phe Leu

1 5

(2) INFORMATION FOR SEQUENCE ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 amino acid residues

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Val Ile Phe Ser Lys Ala Ser Glu Tyr Leu

1 5 10

SUBSTITUTE SHEET (RULE 26)

23

- (2) INFORMATION FOR SEQUENCE ID NO: 5:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

Tyr Leu Gln Leu Val Phe Gly Ile Glu Val

1 5 10

- (2) INFORMATION FOR SEQUENCE ID NO: 6:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 9 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Gln Leu Val Phe Gly Ile Glu Val Val

1 5

- (2) INFORMATION FOR SEQUENCE ID NO: 7:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 11 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

Gln Leu Val Phe Gly Ile Glu Val Val Glu Val

1 5 10

- (2) INFORMATION FOR SEQUENCE ID NO: 8:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 9 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

Ile Ile Val Leu Ala Ile Ile Ala Ile

1 5

SUBSTITUTE SHEET (RULE 26)

24

- (2) INFORMATION FOR SEQUENCE ID NO: 9:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 11 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

Lys Ile Trp Glu Glu Leu Ser Met Leu Glu Val

1 5 10

- (2) INFORMATION FOR SEQUENCE ID NO: 10:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

Ala Leu Ile Glu Thr Ser Tyr Val Lys Val

1 5 10

- (2) INFORMATION FOR SEQUENCE ID NO: 11:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 9 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

Leu Ile Glu Thr Ser Tyr Val Lys Val

1 5

- (2) INFORMATION FOR SEQUENCE ID NO: 12:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 11 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

Gly Leu Glu Ala Arg Gly Glu Ala Leu Gly Leu

1 5 10

SUBSTITUTE SHEET (RULE 26)

25

- (2) INFORMATION FOR SEQUENCE ID NO: 13:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 9 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

Gly Leu Glu Ala Arg Gly Glu Ala Leu

1 5

- (2) INFORMATION FOR SEQUENCE ID NO: 14:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 9 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

Ala Leu Gly Leu Val Gly Ala Gln Ala

1 5

- (2) INFORMATION FOR SEQUENCE ID NO: 15:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 9 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

Gly Leu Val Gly Ala Gln Ala Pro Ala

1 5

- (2) INFORMATION FOR SEQUENCE ID NO: 16:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 9 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

Asp Leu Glu Ser Glu Phe Gln Ala Ala

1 5

SUBSTITUTE SHEET (RULE 26)

26

- (2) INFORMATION FOR SEQUENCE ID NO: 17:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

Asp Leu Glu Ser Glu Phe Gln Ala Ala Ile

1 5 10

- (2) INFORMATION FOR SEQUENCE ID NO: 18:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

Ala Ile Ser Arg Lys Met Val Glu Leu Val

1 5 10

- (2) INFORMATION FOR SEQUENCE ID NO: 19:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 9 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

Ala Ile Ser Arg Lys Met Val Glu Leu

1 5

- (2) INFORMATION FOR SEQUENCE ID NO: 20:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

Lys Met Val Glu Leu Val His Phe Leu Leu

1 5 10

SUBSTITUTE SHEET (RULE 26)

27

- (2) INFORMATION FOR SEQUENCE ID NO: 21:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 11 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

Lys Met Val Glu Leu Val His Phe Leu Leu Leu

1 5 10

- (2) INFORMATION FOR SEQUENCE ID NO: 22:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 11 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

Leu Leu Leu Lys Tyr Arg Ala Arg Glu Pro Val
1 5 10

1 5 10

- (2) INFORMATION FOR SEQUENCE ID NO: 23:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

Leu Leu Lys Tyr Arg Ala Arg Glu Pro Val

1 **5** **10**

- (2) INFORMATION FOR SEQUENCE ID NO: 24:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 11 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

Val Leu Arg Asn Cys Gln Asp Phe Phe Pro Val
1 5 10

1 5 10

28

- (2) INFORMATION FOR SEQUENCE ID NO: 25:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 11 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

Tyr Leu Gln Leu Val Phe Gly Ile Glu Val Val
 1 5 10

- (2) INFORMATION FOR SEQUENCE ID NO: 26:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

Gly Ile Glu Val Val Glu Val Val Pro Ile
 1 5 10

- (2) INFORMATION FOR SEQUENCE ID NO: 27:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 9 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

Pro Ile Ser His Leu Tyr Ile Leu Val
 1 5

- (2) INFORMATION FOR SEQUENCE ID NO: 28:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 9 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

His Leu Tyr Ile Leu Val Thr Cys Leu
 1 5

SUBSTITUTE SHEET (RULE 26)

29

- (2) INFORMATION FOR SEQUENCE ID NO: 29:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 11 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

His Leu Tyr Ile Leu Val Thr Cys Leu Gly Leu
 1 5 10

- (2) INFORMATION FOR SEQUENCE ID NO: 30:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 9 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:

Tyr Ile Leu Val Thr Cys Leu Gly Leu
 1 5

- (2) INFORMATION FOR SEQUENCE ID NO: 31:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 9 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:

Cys Leu Gly Leu Ser Tyr Asp Gly Leu
 1 5

- (2) INFORMATION FOR SEQUENCE ID NO: 32:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:

Cys Leu Gly Leu Ser Tyr Asp Gly Leu Leu
 1 5 10

SUBSTITUTE SHEET (RULE 26)

30

- (2) INFORMATION FOR SEQUENCE ID NO: 33:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 9 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:

Val Met Pro Lys Thr Gly Leu Leu Ile
1 5

- (2) INFORMATION FOR SEQUENCE ID NO: 34:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:

Val Met Pro Lys Thr Gly Leu Leu Ile Ile
1 5 10

- (2) INFORMATION FOR SEQUENCE ID NO: 35:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 11 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:

Val Met Pro Lys Thr Gly Leu Leu Ile Ile Val
1 5 10

- (2) INFORMATION FOR SEQUENCE ID NO: 36:
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acid residues
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:

Gly Leu Leu Ile Ile Val Leu Ala Ile
1 5

31

- (2) INFORMATION FOR SEQUENCE ID NO: 37:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37:

Gly Leu Leu Ile Ile Val Leu Ala Ile Ile
 1 5 10

- (2) INFORMATION FOR SEQUENCE ID NO: 38:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 11 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38:

Gly Leu Leu Ile Ile Val Leu Ala Ile Ile Ala
 1 5 10

- (2) INFORMATION FOR SEQUENCE ID NO: 39:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 9 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39:

Leu Leu Ile Ile Val Leu Ala Ile Ile
 1 5

- (2) INFORMATION FOR SEQUENCE ID NO: 40:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40:

Leu Leu Ile Ile Val Leu Ala Ile Ile Ala
 1 5 10

32

- (2) INFORMATION FOR SEQUENCE ID NO: 41:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 11 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41:

Leu Leu Ile Ile Val Leu Ala Ile Ile Ala Ile
 1 5 10

- (2) INFORMATION FOR SEQUENCE ID NO: 42:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 9 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42:

Leu Ile Ile Val Leu Ala Ile Ile Ala
 1 5

- (2) INFORMATION FOR SEQUENCE ID NO: 43:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43:

Leu Ile Ile Val Leu Ala Ile Ile Ala Ile
 1 5 10

- (2) INFORMATION FOR SEQUENCE ID NO: 44:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 9 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44:

Ile Ile Ala Ile Glu Gly Asp Cys Ala
 1 5

33

- (2) INFORMATION FOR SEQUENCE ID NO: 45:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 9 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45:

Lys Ile Trp Glu Glu Leu Ser Met Leu
 1 5

- (2) INFORMATION FOR SEQUENCE ID NO: 46:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 11 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46:

Leu Met Gln Asp Leu Val Gln Glu Asn Tyr Leu
 1 5 10

- (2) INFORMATION FOR SEQUENCE ID NO: 47:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 9 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47:

Phe Leu Trp Gly Pro Arg Ala Leu Ile
 1 5

- (2) INFORMATION FOR SEQUENCE ID NO: 48:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 9 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48:

Leu Ile Glu Thr Ser Tyr Val Lys Val
 1 5

SUBSTITUTE SHEET (RULE 26)

34

- (2) INFORMATION FOR SEQUENCE ID NO: 49:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 11 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49:

Ala Leu Ile Glu Thr Ser Tyr Val Lys Val Leu
 1 5 10

- (2) INFORMATION FOR SEQUENCE ID NO: 50:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 50:

Thr Leu Lys Ile Gly Gly Glu Pro His Ile
 1 5 10

- (2) INFORMATION FOR SEQUENCE ID NO: 51:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 11 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 51:

His Ile Ser Tyr Pro Pro Leu His Glu Arg Ala
 1 5 10

- (2) INFORMATION FOR SEQUENCE ID NO: 52:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 9 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52:

Gln Thr Ala Ser Ser Ser Ser Thr Leu
 1 5

35

- (2) INFORMATION FOR SEQUENCE ID NO: 53:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 53:

Gln Thr Ala Ser Ser Ser Ser Thr Leu Val
 1 5 10

- (2) INFORMATION FOR SEQUENCE ID NO: 54:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 9 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 54:

Val Thr Leu Gly Glu Val Pro Ala Ala
 1 5

- (2) INFORMATION FOR SEQUENCE ID NO: 55:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 55:

Val Thr Lys Ala Glu Met Leu Glu Ser Val
 1 5 10

- (2) INFORMATION FOR SEQUENCE ID NO: 56:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 11 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 56:

Val Thr Lys Ala Glu Met Leu Glu Ser Val Leu
 1 5 10

SUBSTITUTE SHEET (RULE 26)

36

- (2) INFORMATION FOR SEQUENCE ID NO: 57:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 11 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 57:

Val Thr Cys Leu Gly Leu Ser Tyr Asp Gly Leu
 1 5 10

- (2) INFORMATION FOR SEQUENCE ID NO: 58:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 9 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 58:

Lys Thr Gly Leu Leu Ile Ile Val Leu
 1 5

- (2) INFORMATION FOR SEQUENCE ID NO: 59:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 59:

Lys Thr Gly Leu Leu Ile Ile Val Leu Ala
 1 5 10

- (2) INFORMATION FOR SEQUENCE ID NO: 60:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 11 amino acid residues
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 60:

Lys Thr Gly Leu Leu Ile Ile Val Leu Ala Ile
 1 5 10

SUBSTITUTE SHEET (RULE 26)

37

- (2) INFORMATION FOR SEQUENCE ID NO: 61:
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 11 amino acid residues
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 61:

His Thr Leu Lys Ile Gly Gly Glu Pro His Ile
1 5 10

- (2) INFORMATION FOR SEQUENCE ID NO: 62:
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acid residues
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 62:

Met Leu Asp Leu Gln Pro Glu Thr Thr
1 5

SUBSTITUTE SHEET (RULE 26)

Claims:

1. Isolated peptide selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10 and SEQ ID NO: 11.
2. The isolated peptide of claim 1, designated SEQ ID NO: 1.
3. The isolated peptide of claim 1, designated SEQ ID NO: 6.
4. The isolated peptide of claim 1, designated SEQ ID NO: 9.
5. Isolated complex of HLA-A2 and the isolated peptide of claim 1.
6. The isolated complex of claim 5, wherein said peptide is designated SEQ ID NO: 1.
7. The isolated complex of claim 5, wherein said peptide is designated SEQ ID NO: 6.
8. The isolated complex of claim 5, wherein said peptide is designated SEQ ID NO: 9.
9. Isolated cytolytic T cell clone specific for a complex of HLA-A2 and a peptide selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10 and SEQ ID NO: 11.
10. The isolated cytolytic T cell clone of claim 9, wherein said peptide is SEQ ID NO: 1.

11. The isolated cytolytic T cell clone of claim 9, wherein said peptide is SEQ ID NO: 6.
12. The isolated cytolytic T cell clone of claim 9, wherein said peptide is SEQ ID NO: 9.
13. Monoclonal antibody which specifically binds to a complex of HLA-A2 and a peptide selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10 and SEQ ID NO: 11.
14. The monoclonal antibody of claim 13, wherein said peptide is SEQ ID NO: 1.
15. The monoclonal antibody of claim 13, wherein said peptide is SEQ ID NO: 6.
16. The monoclonal antibody of claim 13, wherein said peptide is SEQ ID NO: 9.
17. Method for treating a subject with a cancerous condition characterized by cancer cells which present a complex of HLA-A2 and a peptide molecule selected from SEQ ID NOS 1-11 on their surfaces, comprising administering an amount of the isolated cytolytic T cell clone of claim 9 to said subject, sufficient to lyse said cancerous cells.
18. The method of claim 17, wherein said peptide is SEQ ID NO: 1.
19. The method of claim 17, wherein said peptide is SEQ ID NO: 6.



SUBSTITUTE SHEET (RULE 26)

40

20. The method of claim 17, wherein said peptide is SEQ ID NO: 9.

SUBSTITUTE SHEET (RULE 26)

1/1

Fig. 1*Fig. 2*

SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/03535**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) :A61K 38/00

US CL :424/93.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/93.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
None

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, DIALOG

search terms: HLA-2 complex with peptide, cytolytic T cell clone, MAGE-2 peptides

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Immunogenetics, Volume 39, issued 15 July 1994, De Smet et al., "Sequence and expression pattern of the human MAGE2 gene", pages 121-129, see entire reference.	1-12 and 17-20
Y	WO, A, 94/03205 (KUBO ET AL) 17 February 1994, see entire document.	1-12 and 17-20
Y	Science, Volume 257, issued 10 July 1992, Riddell et al., "Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones", pages 238-241, see entire reference.	1-12 and 17-20



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

12 MAY 1995

Date of mailing of the international search report

13 JUL 1995

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

SUZANNE ZISKA, PH.D.

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/03535

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Science, Volume 254, issued 14 December 1991, Van Der Bruggen et al., "A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma", pages 1643-1647.	1-12 and 17-20

Form PCT/ISA/210 (continuation of second sheet)(July 1992)★

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US95/03535

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
1-12 and 17-20
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐

The additional search fees were accompanied by the applicant's protest.

☐

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/03535

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claims 1-8, drawn to a peptide and a peptide in a complex. Applicants are required to elect one or more species from the group of species as set forth below.

Group II, claims 9-12 and 17-20, drawn to a method for treating a subject with a cancerous condition characterized by cancer cells which present a complex of HLA-A2 and a peptide molecule, comprising administering an amount of the isolated cytolytic T cell clone of claim 9 to said subject, and the cytolytic T cell clone. This application contains claims directed to more than one species of the generic invention. Applicants are required to elect one or more species from the group of species as set forth below.

Group III, claims 13-16, drawn to monoclonal antibodies which specifically bind to a complex of HLA-A2 and a peptide. This application contains claims directed to more than one species of the generic invention. Applicants are required to elect one or more species from the group of species as set forth below.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack Unity of Invention because they are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for more than one species to be examined, the appropriate additional examination fees must be paid. The species are as follows:

species (a), SEQ. ID. NOS. 1 and 2;
species (b), SEQ. ID. NO. 3;
species (c) SEQ. ID. NO. 4;
species (d) SEQ. ID. NOS. 5-7;
species (e), SEQ. ID. No. 8;
species (f), SEQ. ID. NO. 9;
and species (g), SEQ. ID. NOS. 10 and 11.

The species listed above do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: each SEQ. ID. NO. represents a peptide having a different amino acid sequence. However, the sequences set forth in SEQ. ID. NOS. 1 and 2 are similar, SEQ. ID. NOS. 5-7 have similar sequences, and SEQ. ID. NOS. 10 and 11 have similar sequences. Peptides having similar sequences have been grouped together into a species. Therefore, some species consist of multiple peptides while other species do not. The species per se are distinct from each other in view of the differences in amino acid sequence and therefore do not share the same or corresponding special technical feature. The inventions listed as Groups I-IV do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Groups I, II and III are products which are independent and distinct. Group I, the first named product, consisting of the isolated peptides alone and in a complex, does not share a technical feature with the cell clones of Group II or the antibody of Group III. The product of Group I is not used in the method of Group II and does not share a technical feature with the product of Group III since the peptides of Group I are different than the antibodies of Group III in function. The antibody of Group III does not share a technical feature with the method of Group II since it is not required for such a method. Accordingly, the claims are not so linked by a special technical feature within the meaning of PCT Rule 13.2 so as to form a single general inventive concept.

THIS PAGE IS BLANK